hepatitis C treatment

Investigational genotype 1 hepatitis C treatment

harminka — Mon, 03 Nov 2008 10:02:23 -0600

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

Hepatitis C treatment is cost-effective for the US prison population

harminka — Tue, 21 Oct 2008 06:33:46 -0500

Treating all U.S. prisoners who have hepatitis C with the standard therapy of pegylated-interferon and ribavirin would be cost-effective, says a new study in the November issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Tibotec begins enrollment for Phase III study of telaprevir

harminka — Wed, 15 Oct 2008 11:34:35 -0500

REALIZE is the first phase III study to evaluate a specifically targeted antiviral therapy for hepatitis C (STAT-C) across a full range of HCV-patients who failed prior treatment to current standard of care, including null responders -

Positive findings in treating patients with advanced hepatitis

harminka — Thu, 24 Apr 2008 10:20:36 -0500

The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

Scientists see Norwalk virus' Achilles heel

harminka — Wed, 19 Mar 2008 08:52:37 -0500

Using the Canadian Light Source synchrotron, an international team led by University of Calgary researcher Ken Ng has determined the detailed structure of the enzyme the Norwalk virus uses to make copies of its genetic code in order to replicate itself. The information is crucial to developing drugs that could be used to treat outbreaks of Norwalk and other related viruses.

New hope for hepatitis C sufferers

harminka — Thu, 07 Feb 2008 12:36:53 -0600

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

Shorter HCV treatment shows notable success

harminka — Thu, 03 Jan 2008 06:08:17 -0600

Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects.

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

harminka — Fri, 28 Dec 2007 14:57:46 -0600

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need.

Hepatitis C Treatment Reduces Virus but Serious Liver Problems May Progress

harminka — Wed, 07 Nov 2007 06:05:20 -0600

Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon.

Results of Phase 2B trial of Albuferon for chronic hepatitis C

harminka — Mon, 05 Nov 2007 12:21:15 -0600

Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon® (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

New treatment benefits African-American patients with HCV genotype 1

harminka — Fri, 05 Oct 2007 12:29:21 -0500

Patients with hepatitis C treated with combination therapy of pegylated interferon and ribavirin had better outcomes when taking a weight-based dosage of ribavirin compared to a flat dosage.

Effort to Find Cures for Dengue, West Nile, Hepatitis C Diseases

harminka — Fri, 24 Aug 2007 06:06:27 -0500

In an effort to halt the spread of deadly infectious diseases now threatening to reach epidemic proportions around the world, an unprecedented research effort was launched today by IBM, The University of Texas Medical Branch (UTMB), and the University of Chicago to discover drugs to treat and cure dengue fever, West Nile encephalitis, hepatitis C, and a host of related diseases including yellow fever.